Dr. Xiaoyu Zhu and Dr. Aijie Huang on the Efficacy and Safety of TPO Receptor Agonists for Treating Thrombocytopenia Post-Cord Blood Transplantation 2

Dr. Xiaoyu Zhu and Dr. Aijie Huang on the Efficacy and Safety of TPO Receptor Agonists for Treating Thrombocytopenia Post-Cord Blood Transplantation 2

At the 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) conference, the research team led by Professor Xiaoyu Zhu and Dr. Aijie Huang from The First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital) garnered significant attention. Their study on the efficacy and safety of avatrombopag for treating thrombocytopenia following cord blood transplantation (UCBT) was selected for oral presentation (OC33.3), with Dr. Huang delivering the report. This study not only showcases the exceptional capabilities of Chinese research teams in hematology but also contributes valuable insights to the global hematology community. "Oncology Frontier - Hematology Frontier" had an exclusive interview with Dr. Aijie Huang to delve deeper into the research and discuss future plans in the field of UCBT.
BOC/BOA 2024 | Professor Shaohua Zhang: Treatment Strategies for Breast Cancer Patients Post-CDK4/6 Inhibitor Therapy

BOC/BOA 2024 | Professor Shaohua Zhang: Treatment Strategies for Breast Cancer Patients Post-CDK4/6 Inhibitor Therapy

The results of studies such as postMONARCH and Young-PEARL presented at the 2024 ASCO Annual Meeting have sparked a new round of discussions on treatment strategies for patients with HR+/HER2- advanced breast cancer. To gain deeper insights into the significance of these studies and their implications for clinical practice, Professor Shaohua Zhang from The Fifth Medical Center of PLA General Hospital provided a detailed analysis of the relevant research at the 2024 BOC/BOA Annual Meeting.
Professor Jianyun Nie: Discussing Consensus and Controversies in Breast Cancer Diagnosis and Treatment in the South of Colorful Clouds

Professor Jianyun Nie: Discussing Consensus and Controversies in Breast Cancer Diagnosis and Treatment in the South of Colorful Clouds

The 8th Yunling Breast Cancer Summit Forum, hosted by the Yunnan Anti-Cancer Association and the China Medical Education Association and organized by Peking University Cancer Hospital Yunnan Hospital/Yunnan Cancer Hospital/The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Center, Yunnan Breast Cancer Clinical Research Center, Yunnan Anti-Cancer Association Breast Cancer Professional Committee, Yunnan Medical Association Breast Cancer Professional Committee, and China Medical Education Association Breast Disease Professional Committee, will be held on July 14, 2024, in the beautiful spring city of Kunming. "Oncology Frontier" interviewed Professor Jianyun Nie, the chairman of the conference, to share the highlights of this event.
Professor Guojun Zhang: Towering Yunling Mountains, Gathering of Renowned Experts, and Highlighting the New Heights of Breast Cancer Diagnosis

Professor Guojun Zhang: Towering Yunling Mountains, Gathering of Renowned Experts, and Highlighting the New Heights of Breast Cancer Diagnosis

From July 12th to 14th, the 2024 CACA Integrated Breast Cancer Conference and The 8th Yunling Breast Cancer Summit Forum were held in Kunming, Yunnan. "Oncology Frontier" invited Professor Guojun Zhang, the chairman of both conferences and the president of Yunnan Cancer Hospital, to introduce the conference highlights, the hot directions of translational medicine research in breast cancer, and the achievements of Yunnan Cancer Hospital in breast cancer discipline construction. He also shared his outlook on the application prospects of artificial intelligence in breast cancer.
BOC/BOA 2024 | Professor Meng Wu: Major Advances in Lymphoma Treatment Boost Precision Medicine Development

BOC/BOA 2024 | Professor Meng Wu: Major Advances in Lymphoma Treatment Boost Precision Medicine Development

From July 5th to 7th, the highly anticipated 2024 Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO 2024 China were grandly held in Guangzhou. This conference focused on the "2023 Annual Progress in Clinical Oncology in China" selected by CSCO, aiming to deeply analyze the latest research achievements in the field of oncology in China. Based on the actual situation of cancer incidence in the country, the conference specially invited authoritative experts in the field of oncology and carefully selected outstanding papers from the 2024 ASCO conference in various related fields for comprehensive and in-depth interpretation. During the conference, "Oncology Frontier - Hematology Frontier" had the honor to interview Professor Meng Wu from Peking University Cancer Hospital, who shared profound insights and unique academic perspectives on major research in the field of lymphoma.
Expert Interview | Professor Victor Navarro: Management and Challenges of Drug-Induced Liver Injury in Oncology

Expert Interview | Professor Victor Navarro: Management and Challenges of Drug-Induced Liver Injury in Oncology

In the journey of cancer treatment, drug-induced liver injury is a significant issue that cannot be overlooked. The "8th International Forum on Drug-Induced Liver Injury," held on May 25, 2024, focused on the management of drug-induced liver injury caused by anticancer drugs, inviting numerous renowned experts and scholars from around the world for rich academic exchanges. During the forum, we had the honor of interviewing Professor Victor Navarro from the Department of Hepatology at the Einstein Medical Network in Philadelphia, Pennsylvania, USA. He shared his unique insights on the management of drug-induced liver injury in oncology.
Clinical Characteristics and Treatment Strategies for Immune Checkpoint Inhibitor-Induced Liver Injury

Clinical Characteristics and Treatment Strategies for Immune Checkpoint Inhibitor-Induced Liver Injury

Recently, the "8th International Forum on Drug-Induced Liver Injury and the 9th National Conference on Drug-Induced Liver Injury" along withthe release of the 2024 primary care version of  "Chinese Guidelines for the Diagnosis and Treatment of Drug-Induced Liver Injury" was held in the beautiful city of Xiamen. The theme of this conference focused on the management of liver injury caused by anti-tumor drugs, and it featured extensive academic exchanges by numerous renowned experts and scholars from home and abroad. We were honored to have Professor Guruprasad P. Aithal from the University of Nottingham share his insights on the clinical characteristics and treatment strategies for immune checkpoint inhibitor (ICI)-induced liver injury. This in-depth interview with Professor Aithal provides valuable guidance, helping us better understand and manage this potentially severe adverse reaction.
CDM Monthly Review

CDM Monthly Review

Greetings to all experts and colleagues. In this issue of the CDM Monthly Review, we will share six recent articles in the field of portal hypertension diagnosis and treatment (four on diagnostic monitoring and two on multidisciplinary treatment). This issue features reviews by invited experts: Professor Pengyuan He from the Center for Infectious Disease Control at the Fifth Affiliated Hospital of Sun Yat-sen University, Professor Wei Gou from the Hepatology Department at the Qingdao Sixth People's Hospital, and Professor Airong Hu from the Liver Disease Center at the Ningbo No.2 Hospital.
BOC/BOA 2024丨Professor Chaosu Hu: Advances in Immunotherapy and Proton Carbon Ion Therapy for Head and Neck Tumors

BOC/BOA 2024丨Professor Chaosu Hu: Advances in Immunotherapy and Proton Carbon Ion Therapy for Head and Neck Tumors

Traditional treatment for head and neck tumors mainly involves surgery, radiotherapy, and chemotherapy. In recent years, immune checkpoint inhibitors have shown promising potential in treating head and neck squamous cell carcinoma, and new radiotherapy techniques such as proton and carbon ion therapy offer treatment options with reduced radiation toxicity for patients with head and neck tumors. At the recent 2024 BOC/BOA conference, Professor Chaosu Hu from Fudan University Shanghai Cancer Center chaired the head and neck tumor session, sharing and discussing significant research findings from the 2024 ASCO conference with colleagues. Oncology Frontier interviewed Professor Hu at the BOC/BOA conference to further explore the current diagnosis and treatment status and research progress in head and neck tumors.
Professor Uwe Platzbecker: Breakthrough Progress in the Treatment of Acute Promyelocytic Leukemia (APL) — Key Findings from the APOLLO Study

Professor Uwe Platzbecker: Breakthrough Progress in the Treatment of Acute Promyelocytic Leukemia (APL) — Key Findings from the APOLLO Study

Acute promyelocytic leukemia (APL) is a highly aggressive blood disorder, and its treatment has always been a challenge in the field of hematology. Chinese scholars have contributed the arsenic trioxide (ATO) regimen for global APL patients. Since the APL0406 study reported in the New England Journal of Medicine in 2013, all-trans retinoic acid (ATRA) combined with ATO has replaced ATRA combined with chemotherapy as the standard treatment for patients with intermediate and low-risk APL. However, whether this regimen is suitable for high-risk APL patients is still lacking in randomized controlled trial reports. At the 29th Annual Congress of the European Hematology Association (EHA 2024) held from June 13 to 16, 2024, Professor Uwe Platzbecker from Leipzig University in Germany presented the key results of the APOLLO study in an oral report. The study showed that the combination of ATO and ATRA provides a new treatment strategy for high-risk APL patients, offering valuable insights into the current state of APL treatment and guiding future research directions and clinical practices. "Oncology Frontier-Hematology Frontier" specially invited Professor Platzbecker on-site to share the important findings and clinical significance of the APOLLO study.